None listed
Conditions
Brief summary
This study aims to test if it is practical to conduct a one-off multi-disciplinary team (MDT) consultation for patients with advanced non-small cell lung cancer, focussing on survivorship care needs. Who is it for? You may be eligible to join this study if you are aged 18 years or older, have advanced non-small cell lung cancer, and have been receiving your current cancer treatment for at least 6 months without the disease getting worse on scans. Study details All patients who enrol in this study will be invited to participate in a single, 30-minute, multi-disciplinary team (MDT) meeting via a secure, online video-conferencing platform. The meeting will focus on any unmet needs and concerns the participating patient may have related to survivorship, with discussion led by a lung cancer specialist nurse from the hospital. The MDT will include the patient (+/- a family member), hospital doctor, allied health professional, and a member of the patient’s primary care team (ideally the patient’s GP). Prior to the MDT meeting, all patients will be asked to complete a survey to identify survivorship concerns in order to guide the MDT discussion, and they will receive a 15-minute call by a member of the study team prior to the MDT meeting. The patient’s GP will also be asked to complete a 5-minute questionnaire prior to the MDT. After the MDT meeting a survivorship care plan will be produced summarising the discussion at the MDT meeting, and a copy made available to the patient, the patient’s GP and placed in the patient’s hospital record. Three months after the MDT meeting, participating patients and GPs will be asked to complete a short follow-up questionnaire about how acceptable the MDT meeting process was. Later on (4-4.5 months post participating in the MDT meeting) some patients and their GPs will also be invited to participate in an interview to discuss their impressions of participating in the MDT meeting. Rationale It is hoped that this study will show that a MDT consultation is both feasible and acceptable to patients, hospital and community-based health-care providers, and enable further implementation of these consultations to improve the survivorship care for patients living with advanced non-small cell lung cancer.
Interventions
One-off, virtual, survivorship-focussed multi-disciplinary team (MDT) consultation.
MDT consultation conducted within 4 (ideally) to 6 (maximum) weeks post participant recruitment to study
Intervention: MDT-consultation attended by:
1. Hospital-based team (Minimum: 1 lung cancer specialist clinical nurse, 1 allied health staff, 1 oncology doctor*)
*For the doctor representative, attendance during the first 10 minutes only of the MDT consultation is required.
2. Primary-care clinician
3. Patie
One-off, virtual, survivorship-focussed multi-disciplinary team (MDT) consultation. MDT consultation conducted within 4 (ideally) to 6 (maximum) weeks post participant recruitment to study Intervention: MDT-consultation attended by: 1. Hospital-based team (Minimum: 1 lung cancer specialist clinical nurse, 1 allied health staff, 1 oncology doctor*) *For the doctor representative, attendance during the first 10 minutes only of the MDT consultation is required. 2. Primary-care clinician 3. Patient participant (+/- 1 family member) Setting: • Secure online video-conferencing platform • One-off structured discussion of 30 minutes per patient discussed, led by lung specialist clinical nurse Procedure: • Eligible patients identified via hospital clinics, referred by clinicians or self-referred • Consented study participants referred to MDT-coordinator who arranges survivorship needs screening prior to MDT-consultation o 1st standardised participant questionnaire (~20 minutes) o 2nd Brief phone call (~15 minutes) with one of lung cancer specialist clinical nurse OR lung fellow or registrar following completion of participant questionnaire and pre MDT consultation • Structured survivorship MDT consultation (encompassing discussion of unmet survivorship needs and concerns as guided by questionnaire) led by lung cancer specialist clinical nurse with output being the formulation of a structured, individualised Survivorship Care Plan (SCP) • SCP forwarded to patient participant, patient’s own GP, and made available in hospital medical records for hospital-based clinicians
Sponsors
Chris O'Brien Lifehouse
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Educational / counselling / training
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed unresectable locally advanced or metastatic NSCLC 2. Age >/= 18 years 3. Able to understand, speak and read in English without the use of an interpreter 4. >/= 6 months post initiation of current line of systemic therapy without radiological evidence of disease progression (stable disease, complete or partial response on CT performed within 3 months prior to enrolment; or complete or partial metabolic response, or stable disease on PET) 5. Able to give informed written consent 6. Access to computer with internet connection
Exclusion criteria
1. Psychiatric comorbidity that would preclude participation in the study procedures 2. A diagnosis of unresectable NSCLC that is being managed with ‘definitive’ or ‘curative’ intent (eg patients with stage III NSCLC undergoing concurrent chemoradiotherapy followed by consolidation durvalumab)
Outcome results
None listed